• 폴리머
• /
• 제26권5호
• /
• pp.680-690
• /
• 2002

골 재흡수 치료를 목적으로 파미드로네이트를 지속적으로 방출하는 제형으로 제조하기 위하여 락타이드-글리콜라이드 공중합체 (PLGA, 락타이드 : 글리콜라이드 몰비 = 75 : 25, 분자량 20000 g/mole 및 90000 g/mole)를 이용하여 직접압축 성형방법으로 생분해성 웨이퍼를 제조하였다. 약물과 고분자의 함량비 웨이퍼의 두께, PLGA 분자량 등을 조절하여 PLGA 웨이퍼를 제조하였고 이들의 형태학적 특성과 방출거동 및 분해거동을 살펴보았다. 웨이퍼의 제조는 혼합된 분말을 웨이퍼 제작용 몰드에 넣은 후 프레스를 이용하여 일정 압력으로 일정시간 동안 상온에서 가압하여 제조하였다. 제조된 웨이퍼는 약물의 초기함량이 증가할수록 방출속도가 빠르게 나타났으며, 제형의 두께가 두꺼워질수록 시간이 경과함에 따라 약물의 방출속도가 증가하였다. 또한 고분자의 분자량이 큰 것이 작은 것에 비해 상대적으로 초기 약물 방출량이 적고 방출되는 속도 또한 느려져. 저분자보다 오랫동안 약물이 방출되었다. 이러한 약물전달 시스템은 압축성형방법에 의해 제조하므로 제조가 간단하고 약물방출속도를 정확하게 제어할 수 있으므로 이식을 위한 제형으로 제조시 유용하게 쓰일 것으로 예상되었다.

• The Korean Journal of Pain
• /
• 제22권1호
• /
• pp.74-77
• /
• 2009

Implantable intrathecal pump is one of the therapeutic options for intractable pain. A 24-year-old male with complex regional pain syndrome was suffering from right lower extremity pain. He had all modalities of treatment including spinal cord stimulator. However, his pain had been worse in the past 6 months. His visual analogue pain scale (VAS) was 8-10 and he could not sit or walk. Only opioid was thought to be effective. Then, intrathecal pump was considered. We estimated the minimal effective dose of spinal morphine before implantation. 0.3 mg of morphine was injected intrathecally as a starting dose. Dosage had been increased up to 0.8 mg in 10 days. His VAS score decreased from 8 to 5. He could sleep without pain and walk with crutch. Therefore, intrathecal pump was inserted. He could tolerate to pain. This case suggests that intrathecal morphine delivery can provide effective treatment for intractable non-malignant pain.

• Journal of Pharmaceutical Investigation
• /
• 제25권2호
• /
• pp.117-123
• /
• 1995

For the effective administration of narcotic antagonist, the application of sustained release implantable systems with biodegradable polyphosphazene was examined. Using poly[(diethyl glutamate)-co-(ethyl glycinate) phosphazene], the implantable devices containing naloxone hydrochloride were prepared and in vivo implantation studies were carried out subcutaneously in rat and rabbit with this preparation for the biocompatibility and pharmacokinetics. The histological finding in rats at initial time period was the inflammation that occurred focally around the implants, but they were showed subsequent mild and limited chronic inflammations and the irreversible changes such as necrosis and degeneration of the muscle or connective tissues were not observed. Therefore the placebo and naloxone implants are considered to be biocompatible formulations histologically. In pharmacokinetic studies, the release of naloxone from the naloxone implants into blood plasma was maintained in 192 hours, but the initial burst effect was observed. If this problem was solved, the application for the narcotic antagonist sustained release systems can be expected.